Use of compound or medicinal derivative thereof in inhibiting AIM2 protein activity
US12343318B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2023 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | May 24, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided and belongs to the field of protein inhibitory medicines. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as KD=1.56E−6M and KD=5.12E−6M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.